Here we studied the role of IGF-I on the regulation of the sodium/iodide symporter (NIS) gene expression in FRTL-5 thyroid cells. IGF-I did not modify NIS mRNA levels but inhibited TSH-and forskolininduced NIS mRNA expression in a dose-dependent manner. We explored the signaling pathways by which IGF-I mediates the repression of NIS expression. Inhibition of either the MAPK kinase or PKC activities had no effect. Interestingly, inhibition of PI3K blocked IGF-I repression of TSHinduced NIS mRNA and protein levels. This effect takes place at the transcriptional level, as IGF-I inhibited TSH-induced transcription of a luciferase reporter construct containing a 2.8-kb DNA fragment of the rat NIS promoter. The inhibitory effect of IGF-I on the NIS promoter was blocked by the PI3K inhibitor LY294002 and was mimicked by overexpression of a vector harboring the constitutively activated catalytic subunit of PI3K. Using internal deletions of the NIS promoter, we defined a region from ؊1,947 to ؊1,152 responsible for the I ODIDE UPTAKE IS the first step in thyroid hormone biosynthesis (1), the primary function of the thyroid gland. Iodide transport occurs across the basolateral membrane of thyroid follicular cells in an active transport process mediated by the sodium iodide symporter (NIS) (2). Iodide is subsequently incorporated by thyroid peroxidase (TPO) into the thyroglobulin (Tg) molecule. All of these steps are stimulated by TSH, the primary hormone regulating the functions of differentiated thyroid cells. Although TSH regulation of iodide transport has been widely reported (3-5), the cloning of the rat NIS cDNA by Dai et al. (2) allowed the study of the molecular mechanisms involved in TSH regulation of NIS gene expression. TSH, via cAMP, induces the activity of the NIS protein (6, 7) and increases NIS mRNA levels (8). TSH stimulation of NIS mRNA expression in FRTL-5 cells is inhibited by RA (9), TNF␣, ceramide, TGF␤1, and aging (10). The cloning of the rat NIS promoter (11, 12) allowed initiation of the study of NIS transcriptional regulation. A TSH-responsive element was identified between positions Ϫ420 and Ϫ385 (13) and a thyroid transcription factor-1 (TTF-1) binding site was identified between Ϫ245 and Ϫ230 (14). In the distal promoter, Ohno et al. (12) identified a short enhancer, called NUE (NIS upstream enhancer), another important regulatory element for TSH-regulated transcriptional activation. This element contains binding sites for the thyroid-specific transcription factors TTF-1 and Pax-8, and a cAMP responsive element-like sequence. NUE confers thyroid-specific transcriptional activity to the NIS gene and responds to TSH/cAMP. The cAMP response therefore requires the binding of Pax-8 and the integrity of the cAMPresponsive element sequence.
I
ODIDE UPTAKE IS the first step in thyroid hormone biosynthesis (1) , the primary function of the thyroid gland. Iodide transport occurs across the basolateral membrane of thyroid follicular cells in an active transport process mediated by the sodium iodide symporter (NIS) (2) . Iodide is subsequently incorporated by thyroid peroxidase (TPO) into the thyroglobulin (Tg) molecule. All of these steps are stimulated by TSH, the primary hormone regulating the functions of differentiated thyroid cells. Although TSH regulation of iodide transport has been widely reported (3) (4) (5) , the cloning of the rat NIS cDNA by Dai et al. (2) allowed the study of the molecular mechanisms involved in TSH regulation of NIS gene expression. TSH, via cAMP, induces the activity of the NIS protein (6, 7) and increases NIS mRNA levels (8) . TSH stimulation of NIS mRNA expression in FRTL-5 cells is inhibited by RA (9), TNF␣, ceramide, TGF␤1, and aging (10) . The cloning of the rat NIS promoter (11, 12) allowed initiation of the study of NIS transcriptional regulation. A TSH-responsive element was identified between positions Ϫ420 and Ϫ385 (13) and a thyroid transcription factor-1 (TTF-1) binding site was identified between Ϫ245 and Ϫ230 (14) . In the distal promoter, Ohno et al. (12) identified a short enhancer, called NUE (NIS upstream enhancer), another important regulatory element for TSH-regulated transcriptional activation. This element contains binding sites for the thyroid-specific transcription factors TTF-1 and Pax-8, and a cAMP responsive element-like sequence. NUE confers thyroid-specific transcriptional activity to the NIS gene and responds to TSH/cAMP. The cAMP response therefore requires the binding of Pax-8 and the integrity of the cAMPresponsive element sequence.
Insulin and IGF-I are additional important factors for thyroid function that collaborate with TSH in the regulation of thyroid proliferation and differentiation. The biological effects of insulin and IGF-I are mediated by activation of their cell surface receptors, which possess tyrosine kinase activity (15) . After ligand binding, insulin and IGF-I receptor activities converge on the phosphorylation of insulin receptor substrates (IRS-1 and IRS-2), which then act as docking proteins for SH2-containing proteins such as PI3K. The interaction of the PI3K-regulatory subunit p85 with tyrosine-phosphorylated IRS-1 leads to activation of the p110 catalytic subunit. This results in activation of several protein kinases, including Akt and certain PKC isoforms. Grb-2 is another IRS-1-associated protein; their interaction leads to activation of the small GTP-binding protein Ras, which then initiates the Raf-1/MAPK kinase (MEK)/MAPKs ERK1 and ERK2 cascade. Stimulation of any of these pathways can lead to activation/ inhibition of target genes by transcriptional or posttranscriptional mechanisms (16) . Although the insulin/IGF-I signaling pathways involved in the regulation of thyroid-specific genes remain unknown, several reports have shown their importance in regulating thy-roid gene transcription. Insulin and IGF-I stimulate Tg and TPO mRNA expression (17, 18) . Both hormones increase Tg transcription, and their effects are additive to those of TSH/cAMP (17) . Our group has identified response elements for insulin and IGF-I within the Tg (19) and TPO (20) promoters and reported that the hormonal regulation of both genes is mediated mainly by the forkhead thyroid transcription factor-2 (TTF-2), a thyroid-specific transcription factor that binds to the promoter of both genes (21, 22) . In addition, TTF-2 gene expression is stimulated by cAMP and insulin/ IGF-I (23). Insulin and IGF-I also stimulate transcription of the TSH receptor gene (24) .
Here we studied the role of IGF-I in the regulation of NIS gene expression and the signaling pathways involved in IGF-I action. The results show that IGF-I inhibits TSH/forskolin-induced NIS mRNA levels. This effect is PI3K mediated, as its specific inhibitor, LY294002, prevents IGF-I inhibition of TSH induction; this effect was also observed when NIS protein levels were determined. Using transient transfection assays, we show that IGF-I inhibits TSH-stimulated transcriptional activity of a 2.8-kb NIS promoter, but no inhibition was observed using constructs with internal deletions from Ϫ1,947 to Ϫ1,152. When fused to a heterologous promoter, this region inhibits transcription in response to IGF-I, indicating that it contains IGF-I-responsive elements. Presence of the PI3K inhibitor LY294002 prevents IGF-I inhibition, and cotransfection with a constitutively active form of the PI3K catalytic subunit reduces TSHdependent transcriptional activation. Our results show that via PI3K activation, IGF-I interferes with TSH induction of NIS gene expression; we define a region within the promoter responsible for the IGF-I inhibitory effect.
RESULTS

Insulin and IGF-I Do Not Increase NIS mRNA Levels
Insulin and IGF-I are important hormones for thyroid function; both stimulate expression of the thyroidspecific genes Tg and TPO (17, 18) , as well as the transcription factor TTF-2 (23), and potentiate the stimulatory action of TSH on the expression of these genes. We performed Northern hybridization assays to examine the role of insulin and IGF-I in NIS gene expression. Starved FRTL-5 cells were insulin or IGF-I treated, and NIS mRNA levels were compared with those observed in untreated cells or cells treated with TSH or forskolin. TSH and forskolin stimulate NIS expression, as has been extensively described (8) , but neither IGF-I nor insulin has any effect on NIS mRNA levels compared with untreated cells (Fig. 1) .
IGF-I Inhibits TSH-or Forskolin-Induced NIS mRNA Levels
Although neither insulin nor IGF-I increased NIS mRNA content in FRTL-5 cells, we analyzed whether these hormones could regulate TSH and forskolin effects. Starved FRTL-5 cells were treated with TSH (1 nM) or forskolin (10 M), alone or in the presence of increasing concentrations of IGF-I. The results show that IGF-I inhibited the stimulatory effect of TSH or forskolin in a dose-dependent manner (Fig. 2, A and B, respectively). Maximum inhibition of NIS mRNA levels was reached at 100 ng/ml of IGF-I. Like IGF-I, insulin inhibited NIS mRNA expression induced by TSH or forskolin in a dose-dependent fashion; maximum inhibition was observed at 10 M insulin (not shown). These data suggested that insulin and IGF-I may interfere with cAMP induction of NIS mRNA expression.
Neither MEK nor PKC Is Involved in IGF-IDependent Inhibition of TSH-Stimulated NIS mRNA Expression
To further analyze the mechanism by which IGF-I inhibits TSH-induced NIS mRNA expression, we studied the signaling pathways involved in IGF-I action. After binding of IGF-I to its cell surface receptors, a signaling cascade is initiated, leading to the activation of several kinases including MEK and PKC. To assess the involvement of these kinases in the IGF-I effect, we treated starved FRTL-5 cells with the specific inhibitors of these kinases, PD98059, which inhibits MEK activity, and bisindolyl maleimide I (BIS), which inhibits PKC activity, and determined NIS mRNA levels in response to TSH or TSH plus IGF-I. Figure 3A shows the results obtained with these inhibitors as well as with H89, a specific inhibitor of PKA. TSH induction of NIS mRNA expression is only partially inhibited in the presence of H89. This confirms previous observations by Ohno et al. (12) suggesting that TSH induction of NIS gene expression occurs in both a PKA-dependent and -independent manner. TSH retained the ability to in- crease NIS mRNA levels in the presence of PD98059 or BIS. None of these inhibitors (PD98059 or BIS) abolished IGF-I inhibition of TSH induction, indicating that neither MEK nor PKC is involved in IGF-I action. The inhibitors have no effect when added alone and do not substantially affect mRNA levels in cells treated with IGF-I in the absence of TSH (not shown). The lack of any effect in response to PD98059 or BIS was not due to a loss of inhibitor function, demonstrated by immunoblot assays (Fig. 3B) . Starved FRTL-5 cells treated with IGF-I show increased levels of phospho-ERK1/ERK2, downstream targets of MEK (25) , compared with untreated cells; the presence of PD98059 abolished this stimulation (Fig. 3B, upper panel) . BIS activity was examined by determining the activation of the PKC target, protein kinase D (PKD), using a specific antibody that recognizes phosphorylated PKD (26) . The phorbol ester phorbol-12,13-dibutyrate (PDBu) stimulates PKD phosphorylation, but no phospho-PKD is detected in the presence of BIS (Fig. 3B , lower panel). These results clearly indicate that both inhibitors were active at the concentrations used.
Inhibition of PI3K Prevents Suppression of TSHInduced NIS mRNA and Protein Expression by IGF-I
PI3K is one of the central enzymes implicated in insulin and IGF-I signaling. To determine whether PI3K is required for IGF-I inhibition of TSH induction of NIS gene expression, starved FRTL-5 cells were pretreated with the PI3K inhibitor LY294002 before the addition of TSH, forskolin, and IGF-I. LY294002 pretreatment increased NIS mRNA levels in TSH-treated cells and slightly enhanced the messenger level in cells treated with IGF-I (Fig. 4A) . Interestingly, IGF-I inhibition of TSH induction is not observed in the presence of LY294002. Similar results were obtained using wortmannin (25-100 nM), another PI3K inhibitor (not shown). When forskolin was used instead of TSH, the results resembled those found for TSH, except that LY294002 did not increase NIS mRNA levels in forskolin-treated cells. These data suggest that PI3K interferes with NIS gene expression induced by the cAMP signaling pathway. We next determined whether the changes in NIS mRNA levels in response to TSH, IGF-I, and LY294002 correlated with changes in NIS protein levels. Western blot analyses were performed using a specific anti-NIS antibody that reacts with two main NIS species, the mature 80-to 90-kDa form and a partially processed 60-to 65-kDa NIS form (6) . Due to the long half-life of the NIS protein, FRTL-5 cells were maintained for 7 d in starvation medium, before hormone addition, to completely deplete cells of NIS protein (7) . Cells maintained for 7 d in starvation medium have no detectable NIS protein, and TSH treatment of cells led to an increase in NIS protein levels ( Fig. 4C ), as previously reported (6, 7) . IGF-I completely inhibits NIS protein expression in response to TSH, and the presence of LY294002 prevents this effect. All together, the results suggest that PI3K interferes with TSH-dependent NIS mRNA and protein induction and may mediate the IGF-I inhibitory effect observed.
IGF-I Inhibits TSH-Dependent Transcriptional Activation of the NIS Gene
To study whether IGF-I regulates transcription of the rat NIS gene, we cloned a 2.8-kb fragment of the rat NIS promoter, as described in Materials and Methods. This region contains the NUE, a regulatory element necessary for a full TSH response (12) . Luciferase reporter DNA constructs containing the full-length DNA fragment or 5Ј-deletion derivatives were transiently transfected into FRTL-5 cells and assayed for transcriptional activity in response to TSH and/or IGF-I (Fig. 5A ). As previously described (12), the 2,854-bp DNA fragment (pNIS-2.8) showed significant stimulation of transcription by TSH, whereas the 5Ј-deletion constructs, pNIS-2, pNIS-1.2, and pNIS-0.5, which lacked the enhancer, showed no stimulation of transcription or only trace levels, as was the case for pNIS-0.5. IGF-I had no effect on the transcriptional activity of any construct when added alone, although IGF-I inhibited the TSH-induced transcriptional activation of the construct containing the full promoter, pNIS-2.8; this indicates that IGF-I signaling interferes with TSH induction of NIS transcription. To analyze the mechanism of NIS repression by IGF-I, we inserted a region containing the NUE element upstream of the promoter region in pNIS-1.2 (pNIS-NUE-1.2) and pNIS-0.5 (pNIS-NUE-0.5). Transient transfection analyses with these two constructs and pNIS-2.8 showed that all three constructs expressed significant luciferase activity in response to TSH, but only pNIS-2.8 exhibited a reduction in luciferase activity when IGF-I was added together with TSH (Fig. 5B) . These results indicate that IGF-I does not interfere with NUE activation by TSH and requires the region from Ϫ1,947 to Ϫ1,152 for the inhibition of the TSH-dependent stimulation of NIS transcription.
To confirm that this region is IGF-I responsive, the NIS-regulatory region from Ϫ1,947 to Ϫ1,152 was inserted upstream from the ␤-globin TATA box of the luciferase expression vector TATA-LUC (20) . This construct (pNIS-0.8-TL) and the control vector TATA-LUC were transiently transfected into FRTL-5 cells and assayed for transcriptional activity in response to TSH and/or IGF-I. The results indicate that pNIS-0.8-TL shows almost 50% inhibition by IGF-I, both alone or in the presence of TSH, whereas no effect is observed on the TATA-LUC control vector, which lacked the regulatory region (Fig. 5C ). These results clearly indicate that the Ϫ1,947 to Ϫ1,152 region of the rat NIS gene contains IGF-I-responsive regulatory elements.
PI3K Mediates the Inhibition of TSH-Induced NIS Promoter Activity by IGF-I
To investigate whether PI3K was required for the observed IGF-I inhibitory action on NIS promoter activity, we studied the effect of LY294002 on TSH-induced transcriptional activation of pNIS-2.8, alone or in the presence of IGF-I. The results (Fig. 6A ) resemble those obtained in Northern blot assays, i.e. the PI3K inhibitor LY294002 completely blocked IGF-I repression of the transcriptional activation by TSH. These data indicate that PI3K activity is necessary for suppression of TSHinduced NIS gene expression by IGF-I. To ask whether PI3K activation inhibited TSH induction of NIS gene transcription, we next transfected FRTL-5 cells with the pNIS-2.8, pNIS-NUE-1.2, or pNIS-NUE-0.5 constructs, with or without an expression vector for the constitutively active PI3K catalytic subunit, p110-CAAX. Overexpression of p110-CAAX caused a striking reduction in the stimulation of pNIS-2.8 transcription by TSH, thus mimicking the effect of IGF-I (Fig.  6B) . Conversely, the transcriptional activation of pNIS-NUE-1.2 and pNIS-NUE-0.5 by TSH is not affected by p110-CAAX overexpression. These results indicate that p110-CAAX does not block NUE activation by TSH, and that the region between Ϫ1,947 and Ϫ1,152 responds to PI3K activation, leading to inhibition of transcriptional activation by TSH.
DISCUSSION
The data presented here demonstrate that IGF-I inhibits TSH stimulation of NIS gene expression. These results are in accordance with previous reports showing that IGF-I inhibited iodide uptake stimulated by TSH in FRTL-5 cells (27, 28) ; this effect was also seen when the cAMP analog 8-Br-cAMP was used instead of TSH (28) . We also demonstrate that IGF-I interferes with cAMP signaling, because IGF-I prevents the induction of NIS mRNA expression by forskolin. These results, in addition to the reports mentioned above (27, 28) , thus demonstrate cross-talk between IGF-I signaling and the cAMP transduction pathway; this cross-talk may take place downstream of cAMP generation, because IGF-I did not affect the TSH-induced cAMP levels, as reported by Saji and Kohn (28) .
We studied the signaling pathways involved in the IGF-I inhibitory effect on the induction of NIS gene expression by TSH. Using specific inhibitors of the distinct kinases involved in the most important signaling pathways operating in thyroid cells, we found that the presence of H89, a PKA inhibitor, decreased but did not abolish TSH induction of NIS mRNA levels. It is likely that cAMP regulation of NIS gene expression is mediated by PKA-dependent and -independent pathways, as suggested by Ohno et al. (12) . A new cAMP cascade has been identified that involves the guanine nucleotide exchange factor (GEF), called Epac (29) or cAMP-GEF (30) . Epac, which is regulated directly by cAMP, is a GEF for the small GTPase Rap-1 and is expressed in many tissues, including thyroid (30) . In dog thyroid cells, Rap-1 activation has been described in response to TSH/cAMP (31) and, in the WRT rat thyroid cell line, TSH activates Rap1 through a cAMPmediated, PKA-independent mechanism (32). It remains to be determined whether this cAMP-EpacRap-1 pathway is involved in TSH-dependent stimulation of NIS gene expression.
Contrary to observations with H89, the presence of the PI3K inhibitor LY294002 results in superinduction of NIS mRNA levels by TSH, suggesting a role for PI3K in TSH-dependent signaling transduction pathways. These data concur with recent results involving PI3K in the stimulation of thyroid cell proliferation in response to TSH via cAMP (33, 34) . PI3K signaling is thus required for a mitogenic response to TSH but, in view of our results, it inhibits the stimulation of NIS gene expression by TSH. Interestingly, we did not observe this superinduction when forskolin was used instead of TSH (Fig. 4) . One explanation for this result may derive from the fact that forskolin stimulates cAMP production by direct activation of the adenylyl cyclase, thus eliminating possible PI3K activation by G protein ␤␥-subunits, a PI3K activation mechanism (35) . Although it was not the aim of this study to analyze the signaling pathways involved in TSH-dependent activation of NIS gene expression, it would be of great interest to investigate the existence of this possible mechanism of PI3K activation in response to TSH.
IGF-I inhibition of TSH-stimulated NIS mRNA and protein expression was blocked by the PI3K inhibitor LY294002. We observed similar results with wortmannin at nanomolar doses (not shown). The absence of effect in response to PD98059 and BIS should not be attributed to a lack of function, as we observed an inhibitory effect by both compounds in Western blots for phospho-ERK1/ERK2 and phospho-PKD, respectively. The results clearly indicate that PI3K interferes with TSH-induced NIS gene expression and suggest that PI3K may be involved in IGF-I action. Previous data from Cass and Meinkoth (36) suggested a role for PI3K in the regulation of NIS expression. They reported that transfection of WRT thyroid cells with the Ras mutant RasV12C40, which signals preferentially through PI3K, resulted in a reduction of NIS protein levels, whereas Tg protein levels were not affected. It appears that NIS and Tg gene expression are regulated in a different manner. The authors proposed that RasV12C40-dependent signals might also downregulate the expression and/or activity of Pax-8, a transcription factor involved in the regulation of NIS expression (12) , or affect NIS activity through a posttranscriptional mechanism. Before the cloning of the NIS cDNA (2), Saji and Kohn (28) proposed a posttranscriptional mechanism by which insulin/IGF-I regulated TSH induction of the iodide porter system. Although these results are not in doubt, an additional regulatory mechanism at the transcriptional level cannot be ruled out. Taking advantage of the cloning and characterization of the rat NIS promoter (11, 12), we cloned a 2.8-kb DNA fragment of the rat NIS promoter to study the role of IGF-I in regulating NIS gene transcription. Our results from transient transfection assays, with reporter constructs containing the fulllength DNA fragment or 5Ј deletions, confirm the requirement of the NUE for a potent TSH response, as reported previously (12) . We also showed that transcriptional activation by TSH was inhibited by IGF-I, although the extent of inhibition was lower than that observed in Northern blot studies. This difference may be explained by the suggested posttranscriptional regulation (28) and/or the presence of regulatory elements upstream of the DNA fragment studied.
The results obtained with the PI3K inhibitor LY294002 indicated that PI3K activity was required for inhibition of TSH-induced transcriptional activation by IGF-I. This observation was confirmed by the results of transient transfection assays with the constitutively active form of the PI3K catalytic p110␣ subunit, p110-CAAX, showing inhibition of transcriptional activation by TSH. Although there are multiple PI3K isoforms (37), these findings suggest that signaling pathways leading to activation of the PI3K p110␣ subunit could result in the inhibition of NIS gene expression. It nonetheless remains to be elucidated which PI3K subtype, sensitive to LY294002 and wortmannin inhibition, mediates IGF-I effects. To confirm the results observed with PI3K inhibitor, we performed transfection assays with the dominant negative form of the PI3K-regulatory subunit, p85␣⌬iSH2-N. The results did not provide significant information, as transfection with this mutant resulted in the loss of the majority of the cells (not shown), i.e. drastic inhibition of PI3K activity leads to cell death. This concurs with recent reports on PI3K in cell cycle progression in thyroid cells (33, 34) , in addition to its role in cell survival signaling (38) . Added to our findings, these results clearly demonstrate the importance of PI3K in thyroid cell function. Although we have no physiological explanation for the IGF-Iinhibitory effect observed on NIS gene expression, the results with LY294002 and the dominant positive mutant of PI3K suggest that situations leading to activation of the PI3K pathway may affect NIS expression levels. In this respect, activation of Akt, one of the downstream targets of PI3K, has been shown in several thyroid tumors (39). Moreover, the expression level of PTEN, a 3Ј-phosphatase that converts phosphatidylinositol (3,4)P 2 to PtIns(4)P, and PtIns (3,4,5)P 3 to PtIns (4,5)P 2 , thus inactivating Akt, is decreased in neoplasic thyroid cells and in thyroid tumors (40) . These findings and our results may explain the downregulation of NIS expression found in many thyroid cancers (1) . The elucidation of the mechanism by which PI3K downregulates NIS expression will aid in understanding the absence of iodide symporter activity in thyroid tumors.
To delimit the region within the NIS promoter responsible for the IGF-I effect, several deletions of the NIS promoter were studied. The results indicate that IGF-I does not interfere with the TSH activation of NUE. The region from Ϫ1,947 to Ϫ1,152 seems to be necessary for IGF-I/PI3K inhibition of TSH induction of the NIS promoter; it contains IGF-I-responsive elements, as it could inhibit transcription of a heterologous promoter in response to IGF-I. Computer analysis of this region revealed the existence of several TG/ATTT elements; this sequence is the core motif of insulin and IGF-I response elements found in the promoter of several genes that are negatively regulated by insulin/IGF-I (16) . It has recently been reported that a subfamily of forkhead transcription factors, the FKHR proteins, can bind this motif and are targets of PI3K (41) . This evidence suggests that these proteins, or related family members, may confer the inhibitory effect observed on NIS transcription. Additional observations by our group, indicating that the thyroid transcription factor TTF-2 mediates transcriptional activation of thyroid-specific genes by insulin/IGF-I (23), suggest a general role for forkhead proteins in mediating insulin/IGF-I effects on transcription. Further studies will elucidate the role of FKHR proteins on NIS gene expression and will give new insight into the mechanisms by which forkhead transcription factors regulate the transcription of cAMP-stimulated genes.
MATERIALS AND METHODS
Materials
Tissue culture medium, bovine TSH, and bovine insulin were purchased from Sigma (St. Louis, MO). IGF-I was obtained from Peprotech (Rocky Hill, NJ). Forskolin, LY294002, PD98059, H89, bisindolyl maleimide I HCl, and wortmannin were purchased from Calbiochem (La Jolla, CA). Donor calf serum and DMEM were obtained from Life Technologies, Inc. (42, 43) , were diploid, and their doubling time with TSH was 36 h. Cells were cultured in Coon's modified Ham's F-12 medium supplemented with 5% donor calf serum and a six-hormone mixture [1 nM TSH, 10 g/ml insulin, 10 ng/ml somatostatin, 5 g/ml transferrin, 10 nM hydrocortisone, and 10 ng/ml glycyl-L-histidyl-L-lysine acetate; complete medium (42) ]. The effect of hormones and growth factors was studied by starving near-confluent cells for TSH and insulin in the presence of 0.2% serum (starvation medium) for 72 h. For NIS protein analyses, cells were starved for 7 d, after which the ligands were added to culture medium at the following concentrations: 1 nM TSH, 10 g/ml insulin, 100 ng/ml IGF-I, 10 M forskolin, and 100 nM PDBu (unless otherwise indicated). Inhibitors were added to the cells 30 min before hormone addition at the following concentrations: 10 M H89, 50 M PD98059, 25-100 nM wortmannin, 10 M LY294002, and 1 M bisindolyl maleimide I.
RNA Extraction and Northern Blot Analysis
Total RNA was isolated by the guanidinium-thiocyanatephenol procedure (44) from FRTL-5 cells after different treatments. Total RNA (20 g) was separated in 1% agarose gels containing 2.2 M formaldehyde. RNA was blotted onto Nytran filters as suggested by the manufacturer. Methylene blue staining of the blots revealed the integrity of the RNA and the presence of equal amounts in each lane. Hybridization and washing were carried out with the NIS-specific probe (2), labeled by random oligo priming.
Protein Extraction and Western Blot Analysis
Membranes from FRTL-5 cells were prepared with protease inhibitors as described previously (45) . Briefly, FRTL-5 cells were collected and homogenized in a buffer containing 250 mM sucrose, 10 mM HEPES-KOH (pH 7.5), 1 mM EDTA, 2 g/ml leupeptin, and 2 g/ml aprotinin. Cell homogenates were centrifuged (100,000 ϫ g, 60 min, 4 C) to obtain membrane fractions, and the pellet was resuspended in buffer as above. Whole-cell extracts were obtained by resuspending the cell pellet in a buffer containing 50 mM HEPES (pH 7.0), 2 mM MgCl 2 , 250 mM NaCl, 0.1 mM EDTA, 0.1 mM EGTA, 0.1% NP40, 1 mM dithiothreitol, 2 M Na 3 VO 4 , 10 mM NaF, 1 mM phenylmethylsulfonyl fluoride, 10 g/ml pepstatin A, 10 g/ml aprotinin, and 10 g/ml leupeptin. Protein concentration was determined according to Bradford (46) with the Bio-Rad Laboratories, Inc. (Hercules, CA) protein assay kit. For immunodetection of NIS, membrane fractions were diluted 1:2 with loading buffer and heated (37 C, 30 min) before electrophoresis. Total cell extract proteins (25 g) or membrane proteins (5 g) were separated by 8% or 12% SDS-PAGE for phospho-PKD or phospho-ERK1/ERK2 and NIS, respectively, and then transferred to nitrocellulose membrane. Ponceau S staining of the blots for NIS detection showed equal protein loading. Membranes were blocked (1 h, room temperature) in TBS-T buffer (20 mM Tris-HCl, 137 mM NaCl, 0.1% Tween-20, pH 7.5) containing 5% nonfat milk. Western analyses for NIS detection were performed with anti-NIS antibody (1:5,000 dilution) (45) . PKD was detected using a noncommercial antibody to phosphorylated PKD (26) . Commercial antibodies were used for ERK1/ERK2 or ␤-actin immunodetection at 1:5,000 or 1:2,000, respectively. After incubation with antibodies in TBS-T containing 5% nonfat milk, membranes were washed four times with TBS-T buffer and incubated with a streptavidin-horseradish peroxidase conjugate (1:2,000), followed by four washes of 10 min each with TBS-T buffer. Immunoreactive bands were visualized with the Luminol Western blot detection reagent (Santa Cruz Biotechnology).
Promoter Constructs pNIS-2.8 and pNIS-2 DNA fragments from the rat NIS promoter, corresponding to the regions Ϫ2,841 to ϩ13 and Ϫ1,941 to ϩ13 (11, 12) , were amplified from FRTL-5 genomic DNA by PCR, using forward primers with a BamHI (5Ј-GCTATGGATCCCGAAGTG-GCACTCACAACAT GTACC-3Ј) and SacI sites (5Ј-TCCTGC-GAGCTCTAAGCCTCTGCTAGG-3Ј), respectively, and reverse primer with a BamHI site (5Ј-CGCAGGATCCATG-GAGACAGGTGACTCG-3Ј). The fragments were cloned into pGEM-T vector (Promega Corp.), cleaved by BamHI or SacI and BamHI, and subcloned into pBSLuc2 vector (22) . pNIS-1.2 and pNIS-0.5 DNA fragments were amplified from pNIS-2 by PCR, using forward primers with a SacI site (5Ј-CAACACGA GC-TCCAGCCCTCCCTGGTGGC-3Ј; 5Ј-AAGAAGAGCTCCAA-GAGAACCTGAGTGC-3Ј) and the reverse primer described above. pNIS-NUE-1.2 and pNIS-NUE-0.5 A DNA fragment containing the NUE element was cleaved by SacI and inserted into the SacI site of pNIS-1.2 (pNIS-NUE-1.2) and pNIS-0.5 (pNIS-NUE-0.5).
pNIS-0.8-TL
The DNA fragment was PCR-amplified from pNIS-2.8, using the forward primer with a SacI site (5Ј-TCCTGCGAGCTCTA-AGCCTCTGCTAGG-3Ј) and reverse primer with a BamHI site (5Ј-ATGCTGGGATCCTCGCGGTCATGCCGGTGC-3Ј). The fragment was cloned into pGEM-T vector, cleaved by SacI, and subcloned into the TATA-LUC vector (20) . The fidelity of all constructs was confirmed by sequencing on an automatic DNA sequencer (Perkin-Elmer Corp., Norwalk, CT).
Transfection
FRTL-5 cells were plated at 1.5 ϫ 10 6 cells per 90 mmdiameter tissue culture dish, 48 h before transfection. Transfections were performed by calcium phosphate coprecipitation as described previously (47) . Cells were transfected with 2 pmol of test plasmid and 2 g of Rous sarcoma viruschloramphenicol acetyltransferase (RSV-CAT) (48), used to monitor transfection efficiency. PI3K pathway involvement was studied using an expression plasmid containing the constitutively active catalytic PI3K subunit, pSG5-p110-CAAX, or the dominant negative form, p85␣⌬iSH2-N (49). To study the effect of pSG5-p110-CAAX on pNIS-2.8, pNIS-NUE-1.2, and pNIS-NUE-0.5, 2 g of RSV-CAT, 2 pmol of test plasmid, and 2 g of pSG5-p110-CAAX or the empty vector pSG5 (to adjust total plasmid quantity) were used. To study the effects of TSH and IGF-I, transfected cells were cultured in starvation medium (72 h) and then treated with 1 nM TSH and/or 100 ng/ml IGF-I. The PI3K inhibitor LY294002 was studied by addition at 10 M, 30 min before hormone addition. After 24 h, cells were collected for LUC and CAT activity assay, as described previously (50, 51) .
